ArticleJournal of investigative medicine high impact case reports
Infantile-Onset Unverricht-Lundborg Disease: A Unique Case With Severe Neurological Impairment and Positive Family History.
Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive myoclonus epilepsies (PMEs) are a group of genetic disorders marked by myoclonus, epilepsy, and progressive neurological decline. Unverricht-Lundborg disease (ULD) is among the more common forms, though prevalence varies. We present the case of an 8-year-old male with infantile-onset ULD, notable for significant developmental delay and recurrent seizures. The patient developed early myoclonic jerks and tonic seizures, accompanied by cognitive impairment and global developmental delay. Family history revealed similar neurological challenges in siblings. Genetic testing confirmed a homozygous missense pathogenic variant in the cystatin B (CSTB) gene. With antiepileptic medications, seizure control improved, highlighting the role of early therapeutic intervention. ULD results from loss-of-function mutations in CSTB, leading to CSTB deficiency and impaired protease regulation. Although progressive in nature, management with appropriate therapy can reduce seizure burden and improve quality of life. This case emphasizes that PME may present early in childhood with tonic seizures and cognitive dysfunction, and early recognition is essential for optimal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.